Immune globulin derived from the plasma of paid and volunteer donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders.
麻豆原创 Analysis and Insights: Global Intravenous Immune Globulin Therapies 麻豆原创
The global Intravenous Immune Globulin Therapies market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Intravenous Immune Globulin Therapies is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Intravenous Immune Globulin Therapies is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Intravenous Immune Globulin Therapies is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Intravenous Immune Globulin Therapies include Baxter, Grifols, CSL Plasma, Octapharma, Biotest, Kedrion, Kamada, China Biologic Products Holdings and Hualan Biological Engineering, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Intravenous Immune Globulin Therapies is widely used in various fields, such as Immunodeficiency, Autoimmune Disease and Acute Infection,, etc. Immunodeficiency provides greatest supports to the Intravenous Immune Globulin Therapies industry development. In 2023, global % revenue of Intravenous Immune Globulin Therapies went into Immunodeficiency filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Intravenous Immune Globulin Therapies market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Intravenous Immune Globulin Therapies, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Intravenous Immune Globulin Therapies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Intravenous Immune Globulin Therapies revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Intravenous Immune Globulin Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Intravenous Immune Globulin Therapies revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Baxter
Grifols
CSL Plasma
Octapharma
Biotest
Kedrion
Kamada
China Biologic Products Holdings
Hualan Biological Engineering
Sichuan Yuanda Shuyang Pharmaceutical
Segment by Type
Liquid Form
Lyophilized Powder Form
Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Intravenous Immune Globulin Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intravenous Immune Globulin Therapies companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Intravenous Immune Globulin Therapies revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Liquid Form
1.2.3 Lyophilized Powder Form
1.3 麻豆原创 by Application
1.3.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Immunodeficiency
1.3.3 Autoimmune Disease
1.3.4 Acute Infection
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Perspective (2019-2030)
2.2 Global Intravenous Immune Globulin Therapies Growth Trends by Region
2.2.1 Intravenous Immune Globulin Therapies 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Intravenous Immune Globulin Therapies Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Intravenous Immune Globulin Therapies Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Intravenous Immune Globulin Therapies 麻豆原创 Dynamics
2.3.1 Intravenous Immune Globulin Therapies Industry Trends
2.3.2 Intravenous Immune Globulin Therapies 麻豆原创 Drivers
2.3.3 Intravenous Immune Globulin Therapies 麻豆原创 Challenges
2.3.4 Intravenous Immune Globulin Therapies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Intravenous Immune Globulin Therapies by Players
3.1.1 Global Intravenous Immune Globulin Therapies Revenue by Players (2019-2024)
3.1.2 Global Intravenous Immune Globulin Therapies Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Intravenous Immune Globulin Therapies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Intravenous Immune Globulin Therapies, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Intravenous Immune Globulin Therapies 麻豆原创 Concentration Ratio
3.4.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Intravenous Immune Globulin Therapies Revenue in 2023
3.5 Global Key Players of Intravenous Immune Globulin Therapies Head office and Area Served
3.6 Global Key Players of Intravenous Immune Globulin Therapies, Product and Application
3.7 Global Key Players of Intravenous Immune Globulin Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Intravenous Immune Globulin Therapies Breakdown Data by Type
4.1 Global Intravenous Immune Globulin Therapies Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Intravenous Immune Globulin Therapies Forecasted 麻豆原创 Size by Type (2025-2030)
5 Intravenous Immune Globulin Therapies Breakdown Data by Application
5.1 Global Intravenous Immune Globulin Therapies Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Intravenous Immune Globulin Therapies Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
6.2 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Type
6.2.1 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Intravenous Immune Globulin Therapies 麻豆原创 Share by Type (2019-2030)
6.3 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Application
6.3.1 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Intravenous Immune Globulin Therapies 麻豆原创 Share by Application (2019-2030)
6.4 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country
6.4.1 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
7.2 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Type
7.2.1 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Intravenous Immune Globulin Therapies 麻豆原创 Share by Type (2019-2030)
7.3 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Application
7.3.1 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Intravenous Immune Globulin Therapies 麻豆原创 Share by Application (2019-2030)
7.4 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Country
7.4.1 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
8.2 China Intravenous Immune Globulin Therapies 麻豆原创 Size by Type
8.2.1 China Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2019-2024)
8.2.2 China Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2025-2030)
8.2.3 China Intravenous Immune Globulin Therapies 麻豆原创 Share by Type (2019-2030)
8.3 China Intravenous Immune Globulin Therapies 麻豆原创 Size by Application
8.3.1 China Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2019-2024)
8.3.2 China Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2025-2030)
8.3.3 China Intravenous Immune Globulin Therapies 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
9.2 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Type
9.2.1 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Intravenous Immune Globulin Therapies 麻豆原创 Share by Type (2019-2030)
9.3 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Application
9.3.1 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Intravenous Immune Globulin Therapies 麻豆原创 Share by Application (2019-2030)
9.4 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Region
9.4.1 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Intravenous Immune Globulin Therapies 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Details
11.1.2 Baxter Business Overview
11.1.3 Baxter Intravenous Immune Globulin Therapies Introduction
11.1.4 Baxter Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.1.5 Baxter Recent Developments
11.2 Grifols
11.2.1 Grifols Company Details
11.2.2 Grifols Business Overview
11.2.3 Grifols Intravenous Immune Globulin Therapies Introduction
11.2.4 Grifols Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.2.5 Grifols Recent Developments
11.3 CSL Plasma
11.3.1 CSL Plasma Company Details
11.3.2 CSL Plasma Business Overview
11.3.3 CSL Plasma Intravenous Immune Globulin Therapies Introduction
11.3.4 CSL Plasma Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.3.5 CSL Plasma Recent Developments
11.4 Octapharma
11.4.1 Octapharma Company Details
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Intravenous Immune Globulin Therapies Introduction
11.4.4 Octapharma Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.4.5 Octapharma Recent Developments
11.5 Biotest
11.5.1 Biotest Company Details
11.5.2 Biotest Business Overview
11.5.3 Biotest Intravenous Immune Globulin Therapies Introduction
11.5.4 Biotest Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.5.5 Biotest Recent Developments
11.6 Kedrion
11.6.1 Kedrion Company Details
11.6.2 Kedrion Business Overview
11.6.3 Kedrion Intravenous Immune Globulin Therapies Introduction
11.6.4 Kedrion Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.6.5 Kedrion Recent Developments
11.7 Kamada
11.7.1 Kamada Company Details
11.7.2 Kamada Business Overview
11.7.3 Kamada Intravenous Immune Globulin Therapies Introduction
11.7.4 Kamada Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.7.5 Kamada Recent Developments
11.8 China Biologic Products Holdings
11.8.1 China Biologic Products Holdings Company Details
11.8.2 China Biologic Products Holdings Business Overview
11.8.3 China Biologic Products Holdings Intravenous Immune Globulin Therapies Introduction
11.8.4 China Biologic Products Holdings Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.8.5 China Biologic Products Holdings Recent Developments
11.9 Hualan Biological Engineering
11.9.1 Hualan Biological Engineering Company Details
11.9.2 Hualan Biological Engineering Business Overview
11.9.3 Hualan Biological Engineering Intravenous Immune Globulin Therapies Introduction
11.9.4 Hualan Biological Engineering Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.9.5 Hualan Biological Engineering Recent Developments
11.10 Sichuan Yuanda Shuyang Pharmaceutical
11.10.1 Sichuan Yuanda Shuyang Pharmaceutical Company Details
11.10.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
11.10.3 Sichuan Yuanda Shuyang Pharmaceutical Intravenous Immune Globulin Therapies Introduction
11.10.4 Sichuan Yuanda Shuyang Pharmaceutical Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.10.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Baxter
Grifols
CSL Plasma
Octapharma
Biotest
Kedrion
Kamada
China Biologic Products Holdings
Hualan Biological Engineering
Sichuan Yuanda Shuyang Pharmaceutical
听
听
*If Applicable.
